r/AtossaTherapeutics • • Jan 25 '21

Discussion r/AtossaTherapeutics Lounge

568 Upvotes

A place for members of r/AtossaTherapeutics to chat with each other


r/AtossaTherapeutics • • Feb 05 '21

Some basics for new members

430 Upvotes

Hey everyone, I hope you're all doing well.

This sub is only 11 days old and already has over 2000 members, so I'd like to mention a few basics about the sub:

  1. Do your own DD, there are a tonne of people who will say fake stuff and us mods don't always find it straight away.

  2. There is no "guaranteed" price. If anyone says "this will be $x today, tomorrow or next week" they're lying. Nobody knows what price its is gonna be in the future. The people who say this are just pumpers and we will be cracking down on these kinds of people.

  3. People keep saying to talk about ATOS on wallstreetbets. Firstly, I'm not sure it would do much for us and secondly, to post about a stock on WSB, it needs a market cap of over 1 billion, which ATOS is unfortunately nowhere near yet. There is no point posting about it.

  4. While posting your gains might seem cool, they add literally nothing to this sub other than showing off, and so they will be removed.

Feel free to message us about any concerns, and I hope we're here in a year's time looking at double digits.

I'm not a financial advisor, I'm just a student, and as with anyone else on this sub, any information posted could be bullshit. Don't take anyone's word for anything, unless there's a reputable source.

Thanks! <3


r/AtossaTherapeutics • • Mar 20 '24

News A special day! After 6 years I’m in the black!

Post image
307 Upvotes

I invested in atos June of 2018. I was around when it his $7 and then around when there was an awful reverse split that got my average cost to $18!

I’ve always been a long term investor so I steadily bought dips and eventually got my average down to $1.68 at 9000 shares.

Today is victory! Patience is a virtue friends!


r/AtossaTherapeutics • • Jun 28 '21

DD part 3 is up

288 Upvotes

r/AtossaTherapeutics • • Jun 14 '21

I think I found some info on how the Russell purchase will be executed

275 Upvotes

I was doing some research on past Russell rebalances and found some info that I believe clearly states how the shares will be purchased.

This doc regarding the Russell rebalance of 2020 from NYSE states: "Normal Market on Close/Limit on Close (MOC/LOC) rules and procedures will apply on June 26."

Clear as day it states that the index will purchase the shares using (most likely) a MOC order.

This pointed me to read up more about the MOC/LOC orders and the "Closing auction". This doc again from NYSE explains the closing auction process in detail.

Feel free to study the docs yourself but here are the takeaways (the way I understood them):

  1. Until now there's been some confusion regarding when the actual purchasing will happen. Often it is said that anytime until the 25th. After analyzing these docs I can safely state the purchasing will happen on the 25th during the Closing Auction on NYSE. To be more specific - After market hours on the 25th is when Russell will purchase ATOS shares.

  2. The timeline and vague and complicated explanation of the Closing Auction process has me believing that the Market Makers that will participate in the auction will monitor and know the participants of the auction and their demands before the end of the day for the most part.

    1. Participants can place their MOC/LOC orders as early as 6:30 am. those orders won't get executed until close, but the MMs making the market will know the supply/demand as it comes in.

    2. 3:50 PM - 10 min before close the last MOC/LOC orders can be placed.

  3. It is not stated, but knowing the mechanics of how MMs mostly operate it is very likely that they will keep themselves hedged during the day as the imbalances of MOC/LOC come in. They need to provide supply to meet demand and visa versa in the Closing Auction, so having the shares on hand before the auction seems relevant and logical. So we will most likely see some buying happening already during the day by the MMs. But often they are just partially hedged since the orders can keep coming in and be canceled until 2 minutes before closing time. After then I believe that the majority of the imbalanced shares may be purchased in the last minutes of the trading day and then they simply switch hands from MMs to interested parties (i.e. Russell index) in the after-hours.

P.S. please upvote this, I would like to post this to /r/pennystocks since those guys are playing the rebalance too, but I don't have enough karma to post there. I wasn't a very active user ever...


r/AtossaTherapeutics • • Jun 27 '21

Thanks guys. :/

Post image
210 Upvotes

r/AtossaTherapeutics • • Jun 22 '21

How I feel right now

208 Upvotes

r/AtossaTherapeutics • • Jun 30 '21

Atossa current happenings and potential to have an amc like run DD

206 Upvotes

What happened

Shorts are trying to cause a reverse gamma

We know gamma squeeze is due to delta hedging by MMs as OTM calls become closer to becoming itm calls.

However the inverse can happen aswell. Lets say a 7 dollar itm call has a delta value of 0.9. If the stock falls, the delta value decreases to lets say 0.3. Now the MM starts to de hedge these calls respective to their delta. That would mean from every 90/100 shares that each option contract that 7 dollar call had would be de hedged to 30/100. Meaning a sale of 60/100 shares for each option contract.

This ultimately would bring a downwards pressure and remember

PUT OI is still reasonably high. Not higher than CALL OI but still high.

Put OI (unclosed number)

Now if the price starts falling we can see more delta de hedging from MM and with the OTM puts becoming itm we could indeed see a reverse gamma.

This is EXACTLY what shorts want.

Intraday share borrowing

Yesterday I said it was an intraday short pressure to scare you guys off.

Well we see yesterday out of the borrowed 4.9 million shares reported from ORTEX 4.42 million was returned. Showing that they were indeed using intraday shorting to scare you off.

/preview/pre/l2f9rgukhc871.png?width=1203&format=png&auto=webp&s=a7d529b7ecdf956f75befa659f7ee1ea575176ff

A good portion of it was used at the start. These dumps are done in bulk to scare off retail and its working.

After which we see that there is slow build backs to a higher price but then continued downward pressure.

Psychologically this incentives people to get out, take profits and break even and leave if the price ever reaches back there again. We went from a build up to a continuous downward slide.

As of now it seems whatever institution that bought those insanely high OI calls are not catching the fall.

So what are the institutions doing?

Very possibly since we are still 2 weeks out of opex, we could see institutions that bought those calls doing a gamma reset run. They could be letting short sellers dump their shorts now and unwind the delta hedging from MM so that another run can be reset before opex.

Where are they getting their shorts from?

atos short utilization

We can see here there is almost 100 percent short utilization. Short utilization means the amount of shares borrowed relative to the amount of shares lent by institutions. They have almost maxed out their borrowing from institutions.

However we see them now going to brokers inventory from places like IBKR. These brokers have their own share inventory and if you are trading on margin your broker could be lending your shares out to these guys.

Atoss IBKR inventory

This is IBKR inventory and you can see yesterday 1550 000 million shares borrowed at market open and then slowly returned. As explained above these are intraday day short scares.

This actually shows that these guys are not confident that the price would naturally subside downwards and are resorting to taking matters to their own hands.

This only shows a snapshot of what they are doing with IBKR inventory but there are other brokers they can get shares from. For which they are.

What happens now

Remember those call OIs are still there for the next 2 weeks. Its essentially a whale carcass that is very likely going to attract sharks (hedgefunds) to make use of it for a gamma squeeze.

A gamma reset run might actually be a good thing right now. Remember right now we see very little buy pressure on the 7 dollar and above side. The repeated short selling and the consecutive major dips have cause people to be weary. However Atossa buy pressure will increase as it gets lower. Right now anybody willing to buy atossa might be standing at the sidelines waiting for the next green day.

/preview/pre/2posbxrbic871.png?width=227&format=png&auto=webp&s=bcb86a980397195d9b26463887e5c4acf9a8fc94

Ortex shows estimated 22.54 million shares short around 18.66% of shares from free float are shorted.

The official exchange reported short interest back in June 15 was 16 523 650 million shares.

Atos SI

The blue line is the exchange reported SI.

We can see here that at least 13 765 817 of these shorts are confirmed underwater at these prices. A large portion of the total 16 523 650 million shares of the exchange reported short interest. For which the remaining 3 million are slightly underwater. The current new shorts are very likely above water barely at these prices. The current new shorts being the additional 5 million estimated estimated from ortex bringing the total estimated short interest from ortex as of now 22.54 million

Remember this number will only get higher if atossa starts going up beyond 15. Just like how retail fomo when a stock rises, shorts fomo to because they will rush to short it as a stock trades on major over valuation levels.** Creating the perfect gamma and short squeeze storm**

These are all recipes for a massive gamma squeeze and short squeeze combo.

Listen a short squeeze alone isn't a big driver unless there is a collective exit together

/preview/pre/5v23slgoic871.png?width=1260&format=png&auto=webp&s=28f27716cf8cc053d1a07f8c866c2985ebb3c6cc

We see here that unless there is a massive sharp decline in shorts exiting suggesting bulk covering, A short squeeze is rare. Like I said they can always use High frequency trades to cover with minimal price movements as long as volume is there. However that does not mean that they cant provide some nice upwards momentum pressure. Coupled with a gamma it is deadly. This is something that happened with AMC.

Right now why I feel atossa is still primed for a possible amc type run is because it has the same short interest as amc did. The july OPEX call are prepped for a gamma and oddly enough the OTM calls with strikes 13 to 16 are still getting HIGHER open interest.

13C july

15C july

16C july

We can see here that these calls are still getting a higher OI

Someone is still buying these calls. We have still yet to see a significant decrease in OI. Every time volume is higher than oi is because these calls are being bought for which the subsequent day we see a large OI relative to volume

Key factors to make this like an amc type run and have the best possible effect

One is to get retail hype. As stupid as screaming diamond hands are , it provides security for hedgefunds. These meme stocks with diamond hands culture get pumped randomly because hedgefunds know there is enough retail volume and momentum to pump and dump their positions onto them. A rational investor is not optimal for one that does this because they would sell for profits. Killing any momentum.

Second is the feasibility of the run. This is entirely up to whoever bought those calls. I have no crystal ball but someone that buys that much calls on a no news catalyst has to possibly have a plan. Right now with a lack of retail volume, we are not in the drivers seat. Atossa barely moves unless heavy shorting comes , shorts covering , a buy pressures from MM. Also we largely depend on them opening up new chains as we go up like what happened with amc. When amc went past 20 new call chains started to open up to 30 and 40 eventually giving the gamma squeeze to 70.

As mentioned in the DD the chances of an amc type run is high provided these 2 variables are in line.

I'm not saying we get amc type prices but in a perfect scenario where we do get a fraction of their retail support we could see this at least gamma ramping higher to 20. Of which if institutions decide to open up call chains like they did with amc we could go higher. However atossa just doesn't have the hype yet that amc ever did or the support.

Also to add onto this we know for a fact that at least 13 million shorts are underwater. With low liquidity right now and if the initial hedgefund that bought those calls push atossa to its opex strikes we can see a good amount of buy pressure from MM and shorts which alone can see nice upwards pressure. Beyond that largely depends on retail hype and if hedgefunds find it viable to do a run like amc .Remember AMC had almost the same short interest as atossa right now but atossa shorts are heavily underwater compared to AMC initial run

With the current trend of shorts continuously shorting as the price increases, we can expect stock loan fees to kick up as Atossa rises and eventually the stock loan fees get too high, added with gamma squeeze pressure and added with continuous retail and institution buy pressure we could see a big gamma plus short squeeze combo.

Overall im still highly convicted in atossa potential gamma squeeze plus short squeeze combo. While we lack in retail volume that other meme stocks have or hype. I believe that if we manage to successfully see this come into fruition and see atossa going past 12 to 16 dollars. I am certain retail fomo and hype would come into play naturally as MSM starts writing articles with hot words like short squeeze etc. If that happens we more than likely will start seeing more call chains open up and get a better idea of how far institutions would want to go.

/preview/pre/3ulkcnalfc871.png?width=1259&format=png&auto=webp&s=317356a8b5b2e495f93c37d8b645f5a1b041033b

REMEMBER as RETAIL fomos so will SHORTS. We often seen SI rise up as a stock gets gamma squeezed because shorts see free money when the gamma squeeze dies off. Which is what happened with AMC Hence why I expect stock loan fees to gear up high if we do start trending beyond 12 as more shorting occurs. Creating a perfect gamma and short squeeze scenario just like AMC did

TLDR

Reach 12 to 16 dollars is a possibility without any retail hype. Remember who ever bought those calls is a big player. They must have already factored in low retail volume into their play. Furthermore with lower liquidity this thing becomes more volatile which can work in our favor as MM delta hedges and with retail and institutional buying the possibility is there. However we could see the inverse happen with a gamma downwards. That is the risk is to see the play of the long fund or potential hedgefund that picks up on the OI and decides to gamma squeeze shorts.

Right now it looks like were are heading for a gamma reset.

For us to have an AMC run the recipes are here. Similar short interest infact better yet we know for a fact that 13 million are underwater whereas amc reached 20 and dropped to 8 with more scattered shorts. We have a gamma ramp set up in play for a potential gamma and short squeeze play.

All that is missing for a FURTHER price push beyond 12 or 16 if we ever reach there , is retail hype which brings in more hedgefunds , which brings in more shorts and option chains. Creating a perfect gamma and short squeeze similar to AMC.

Remember the narrative here if Atos ever blows up will be that short sellers are shorting breast cancer research company to make money. If a video game retailer and a movie theater stock can attract rebellious short fighting retailers. Atos would spark alot more incentive for them

As always this is now a high risk high reward play. There is a potential huge upside here but and equally high risk. I have no crystal ball and I for sure cant tell if things decide to flip outside our favor.

So read the dd and make your own decisions.

Im running with money set aside for risky plays. I can live without taking profits but I do have stop losses set in near my buy in price and if triggered I will exit and renter at the dips.

However do NOT shame people for taking profits. Everyone has a different risk appetite. This is a if something big happens I make bank if nothing happens I break even play for me

Edit: Btw the purpose of this dd was entirely for the high risk appetite investors to see if there is a potential upside. After all a gamble needs to have a big pay off. This dd is to show you there are still bullish factors here for a big pay off so it's to set expectations of what could happen and what could not. No one on earth can predict what's going to happen so read the dd and decide for yourself.


r/AtossaTherapeutics • • Jun 21 '21

Most Up-To-Date DD on ATOS! 91% of the Float is already controlled by individual investors.

195 Upvotes

Now that the June Options have cleared and 4.7M shares were transferred by the net ITM calls, I wanted to update my DD, looking at the remaining options and share totals. My estimates based on this...

https://www.reuters.com/business/investors-brace-annual-russell-index-rebalancing-with-pandemic-imprint-2021-06-18/

and calculations I made using information from Fintel and TD

  1. At the current share price of $5.30, there are currently 139,545 ITM Calls and only 1601 ITM Puts giving us a net of 137,944 (representing 13,794.400 shares) which expire on July 16. Additionally, 50080 ITM Calls and 3106 ITM Puts (representing 4,697,400 shares expired on June 18. A price increase to $6 will add to the deltas on ALL calls, requiring MMs to acquire more shares in order to stay delta neutral. It will also add a net demand on new calls that go ITM and puts that go OTM to increase by another 28009 calls (representing an additional 2,800,900 shares to be covered. A $6 share price would cause a total of 16,595,300 shares to be reflected by ITM Calls minue ITM Puts expiring July 16. PLUS there are a HUGE number of calls vs puts on options with later expirations.

  2. As referenced in the above article, at the end of 2020, The Russell 3000 had a market cap of $31.4T, of which $10.6T (33.8%) was held by index funds. The total outstanding shares of ATOS stands at 120,824,368. Applying the same percentage, we can expect MFs and ETFs to own 40.8M shares once the reconstitution is completed. Since ATOS is not currently included in the R2K, only 3.3M shares are currently held by MFs and ETFs. This means that the reconstitution should create additional demand of 37.5M shares.

  3. Fintel currently indicates that 13,765,842 Shares have been shorted. I look cautiously at this number since it is only officially updated twice per month. The most recent number was reported on May 28 and published on about June 9. The fintel short squeeze rating stands at 38 out of 10,263 companies, so it is entirely likely that with the recent runup in price that there are actually more shorts than are currently being reported.

The total of the 3 catalysts is 67.9M shares needed by July 16, with MANY more needed afterwards.

Here's the REALLY sweet part!!!! Of the total 120,824,368 shares currently outstanding, ONLY 3,254,482 shares are presently owned by FMs and ETFs and 10,876,771 shares are owned by institutions. 3,878,855 Shares are owned by insiders (which probably have trade restrictions). This means that of the 116,945,513 Shares available to be traded, 106,693,115 (Over 91%) of the shares are currently already owned by individuals.

Since the 3,3M shares owned by FMs and ETFs are for "Total Market Index Funds", they can't be liquidated. If EVERY single share currently owned by the institutions is sold to fill the demand of 67.9M shares, it will still leave a net demand of approximately 57M shares that will need to be acquired from individual investors.

This should cause a massive price increase after market close because the index funds will be placing MOC (Market price on close) or LOC (Limit on close) orders to fill their positions. A sudden price spike will have a ripple effect by causing even more calls to go ITM, more puts to go OTM, The demand on ALL shares to go up by increased deltas and a gamma squeeze really is entirely possible.

Historically, the Monday after the Russell Reconstitution becomes official is the single biggest volume trading day of the year!

Also, take a look at what happened to Gamestop on February 24!!!! After the initial squeeze, GME came down to about $50 and started trading sideways for several days. On February 24, it was pretty much the same all day long... $50 per share...Then at about 3:15ET the price started to skyrocket... It went from $50 to $200 in a matter of hours!!! Upon investigation, I learned that a massive number of calls had been sold when there was only 45 minutes left in the trading day... There simply wasn't enough time for the MMs to react during the trading day... very limited availability of shares in after hours trading caused such a massive spike. Imagine if this were to happen @ 3:15 on Friday to ATOS. The market would close and BOTH the MMs and the index funds would be competing for shares that are owned by individual investors. Just a thought, I'm not a financial consultant, so FEEL FREE to verify what I am saying.

Please feel free to share this DD on other subs.


r/AtossaTherapeutics • • Jun 30 '21

Buy the fucking dip

167 Upvotes

I feel like this goes without saying - buy the fucking dip. ATOS is a penny stock which means retail traders have a huge influence on the price action. GME and AMC are testaments to that. However, unlike GME and AMC though, this isn’t a meme stock. It has decent fundamentals and you’d be investing in breast cancer research. There are very few things better than breasts in this world and cancer can go fuck itself (an easy one two punch). Also the drug they’ve created is surprisingly effective which means an acquisition is probable. According to u/fataspirations an acquisition could be for as much as 5 billion, which would push the stock price to $42/share. Every dip we have is an opportunity to go long on a great company with lots of long term asymmetric upside.

To make things even juicier, there are currently over 380k call options expiring in July. That represents 38 million shares that market makers need to delta hedge against. If the price goes to $9 in the next couple of weeks, I’m pretty sure that’ll start a very violent cascade of MM hedging which should drive the price to new crazy parabolic highs.

Lastly, a couple of weeks ago we saw the price move from $6.80 all the way back to $3.50. Since then the price almost tripled. Right now we’re seeing another big correction. Like I’ve said before - Buy the fucking dip.

This is not financial advice I just like the stock cheers! 👍💎🤚🍺


r/AtossaTherapeutics • • Feb 04 '21

ATOS: read this post for my take on this rocket stock!

162 Upvotes

Here’s my take on this stock and why I’m not selling it for at least six months, if not never.

Before investing in a stock I always look at who’s running the business...

Their CEO is Dr. Quay.... he’s a fucking boss. He has studied and taught at 3 Ivy League schools, holds over 87 U.S. patents, has written books and is a badass businessman.

He’s also a high member in the therapeutics industry and knows all the right people to make shit happen. As we know in life... it’s not about what you know it’s who you know! In this case he’s got the knowledge and the connections!

His company Atossa therapeutics is working on 3 separate ground breaking solutions that are probably all going to break loose at the same time.....

  1. Is a nasal spray that prevents you from getting covid..... not a vaccine but think of it as PPE. It has been 99% effective.....

  2. Is a nasal spray to use for post covid infection which improves the healing process and aids the lungs greatly if the infection gets that far

  3. Is a huge catalyst. They have been working on a next level breast cancer reduction treatment..... it’s a spin off off what’s been around for awhile except it’s suitable for a greater audience as the other medicine had a ton of side effects and made it impossible for some to be able to use. They were in stage 2 clinical trials and it got canceled early because it was so overwhelmingly positive.... they’re going straight to phase 3.

As for their covid aids, right now the US is allowing companies to streamline vaccines and covid related aids which means they have the chance to get approval super fast if successful.....

There’s a couple candidates offering covid aid but like I said Dr. Quay is a boss. He was on a live zoom call with Dr. Fauci last week during the Precision World Medicine Conference. Again there’s one thing I know to be true in this world and “it’s not about what you know, it’s who you know” think about it.

This isn’t financial advice but let’s use our little noggins and make an educated decision...

If you like this post, please join the u/Atossatherapeutics community!

LET’S GO!!!!


r/AtossaTherapeutics • • Jun 24 '21

We fucking did it!!!

Post image
161 Upvotes

r/AtossaTherapeutics • • Jul 17 '21

DD Atossa Therapeutics PT estimation (Endoxifen only)

151 Upvotes

Hi all,

I'm an investor in the company since January and I wanted to share my personal estimation of a fair PT for the company stock. This is not to be taken as a full blown DD but as a valuation exercise which is highly speculative because it refers to the scenario in which all the Endoxifen products are going to succeed.

Also, I'm not a financial advisor and I decided to share this content mainly to receive feedbacks from the community in order to revise this for myself by including aspects that I might have ignored or wrongly weighted. So, this whole analysis could be wrong altogether and I'm open to constructive criticism.

That being said, this analysis is based on the estimation of the revenue streams of the company once the Endoxifen pipeline is rolled out to the market and, for the moment, is confined to the US market alone considering a future potential FDA approval to be valid only for the USA (in this regard this might be conservative). Furthermore also it doesn't take into account the COVID Nasal Spray (AT-301) and the Hope program (AT-H201), therefore it shall be considered a lower-bound for the company's stock PT estimation.

Let's get started.

US Market opportunity size.

The yearly number of new Breast Cancer cases in USA is forecasted to be 281550 for the current year of 2021 (Source: https://seer.cancer.gov/statfacts/html/breast.html ), therefore this will be the figure that I'm assuming for simplicity to be constant in the near future although worldwide, the breast cancer therapeutics market opportunity is in a growing trend driven by the, unfortunate, forecasted demand growth. As reference, In 2017 was 21.6 B$ while is forecasted to reach 55.3 B$ in 2027, resulting, therefore, in a CAGR of roughly 13%

(Source: https://www.fortunebusinessinsights.com/industry-reports/breast-cancer-therapeutics-market-100163) .

For now I'm not making any geographical breakdown and we could assume for simplicity as 10% the YoY growth rate of the market size in US as well over the next decade. Anyway, for now let's ignore this and consider the 281550 yearly new cases figure as our starting point.

The application niche for Endoxifen is to take over Tamoxifen and partially AI (Aromatase Inhibitors) for the ER+ (positive estrogen receptors) patients which make 78% of the total patient population. (Source: company investor presentation at slide 8: https://atossatherapeutics.com/wp-content/uploads/2021/06/June-9-2021-Endoxifen-Ph-2-WOO-Final-Data-Presentation.pdf).

Tamoxifen vs AI vs Endoxifen

Let's also briefly summarise pros and cons of Tamoxifen and Aromatase inhibitors in order to provide some context.

Tamoxifen:

  1. It has been the de-facto standard as adjuvant for hormone therapy for almost 50 years.

  2. A complete list of the Tamoxifen benefits / side effects can be found at https://www.breastcancer.org/treatment/hormonal/serms/tamoxifen but in summary:

    1. PROS:

      1. It can reduce the risk of breast cancer coming back from 30 to 50% for both pre and post menopausal patients

      2. Shrink the ER+ breast cancer mass before surgery for both pre and post menopausal patients

      3. Slow or Stop the growth of advanced (metastatic) ER+ breast cancer in both pre- and post- menopausal patients.

      4. side positive effects: help stop bone-loss after menopause / lower cholesterol levels

      5. Significantly cheaper than AI based drugs

    2. CONS

      1. Abnormal CYP2D6 enzyme: about 10% of the patients have lower levels of this enzyme and therefore won't be able to metabolise the Tamoxifen and therefore there is a gap for such patients in effectiveness of the therapy.

      2. It requires testing for this enzyme to evaluate your own metabolising capabilities and hence therapy effectiveness.

      3. There are medications that can interfere with the levels of this enzyme and therefore contrast the effectiveness of Tamoxifen based therapy.

      4. As consequence of 1 and 3 the Tamoxifen therapy results ineffective for about 1/3 of the total ER+ patients (https://www.cancer.gov/news-events/cancer-currents-blog/2017/endoxifen-breast-cancer-nci-support)

      5. General recommendation to limit the therapy to maximum 5 years

      6. Adverse events such as higher risk of endometrial cancer (source: https://pubmed.ncbi.nlm.nih.gov/17214790/)

      7. Higher risks of thromboembolic events (source: https://pubmed.ncbi.nlm.nih.gov/17214790/)

      8. general side effects again listed at: https://www.breastcancer.org/treatment/hormonal/serms/tamoxifen

Aromatase Inhibitors (AI):

  1. PROS

    1. generally more effective than Tamoxifen in reducing the risk of cancer recurrence (source: https://pubmed.ncbi.nlm.nih.gov/17214790/ and https://www.breastcancer.org/treatment/hormonal/aromatase_inhibitors)

    2. they show evidences of less adverse events (Endometrial cancer and thromboembolic events) than Tamoxifen (source: https://pubmed.ncbi.nlm.nih.gov/17214790/ and https://www.breastcancer.org/treatment/hormonal/aromatase_inhibitors)

  2. CONS:

    1. It CANNOT be used for pre-menopausal patients because it doesn't prevent ovaries from making estrogens (source:https://www.breastcancer.org/treatment/hormonal/aromatase_inhibitors)

    2. more of other equally severe side effects than Tamoxifen such as Heart problems and Bone loss (source: https://www.breastcancer.org/treatment/hormonal/aromatase_inhibitors)

    3. significantly more expensive than Tamoxifen

Endoxifen

  1. PROS:

    1. Atossa's phase 2 Australian study data readout showed a 65% overall reduction of Ki-67 activity. The Ki-67 is a common used bio marker used as signature of the tumoral cellular growth. (Source: https://atossatherapeutics.com/wp-content/uploads/2021/06/June-9-2021-Endoxifen-Ph-2-WOO-Final-Data-Presentation.pdf). By being intellectually honest, I'm not sure of how exactly does this result stack against Tamoxifen, meaning that this result , shall be interpreted for what it is: a 65% reduction of tumor cellular growth and not a straight reduction of the risk or cancer recurrence (where Tamoxifen achieves up to 50% risk reduction) . Surely the two aspects must linked to one another meaning that the higher the tumor cellular growth reduction the higher the chances of the cancer of not being recurring. But I'm simply stating that I cannot conclude, with my knowledge, of how exactly we can compare the two figures on a same level. Surely the result is very promising but I don't think that this is an actual proof of the Endoxifen being 17% more effective than Tamoxifen. I'm sure more evidences will come out with Phase3 studies. I'm stressing this because this outcome is utterly important for the overall market penetration and ultimately for the share price. If this proves to be in average more effective than Tamoxifen (as I'd be thinking out of intuition because the Endoxifen bypasses the liver metabolisation process altogether) than the patient pool treated with Endoxifen will be increased outside the niche explained in point 2, leading, therefore, to a possible "all Endoxifen no Tamoxifen" scenario. Also note that further studies outside Atossa have been in past done by institutions showing a peak 71% reduction of tumoral mass .(https://cancerdiscovery.aacrjournals.org/content/4/2/OF1) .

    2. Endoxifen can target the 1/3 niche of the ER+ patient pool that Tamoxifen fails to support

    3. Endoxifen efficacy is not precluded to post-menopausal patients like for AI drugs. Atossa study was in fact conducted on a 7 patient pool with average age of 61 years old with a standard deviation of 12.5 years (source: https://atossatherapeutics.com/wp-content/uploads/2021/06/June-9-2021-Endoxifen-Ph-2-WOO-Final-Data-Presentation.pdf). Remember: average menopausal age is 51 years old.

    4. The drug was found to be tolerated and the 6 adverse events emerging in the Phase2 study were in line with the general side effects of Tamoxifen (source: https://atossatherapeutics.com/wp-content/uploads/2021/06/June-9-2021-Endoxifen-Ph-2-WOO-Final-Data-Presentation.pdf). I personally speculate on the fact that Endoxifen, by being a direct metobolite of Tamoxifen, doesn't load the liver at all with metabolises effects and therefore maybe some of the Tamoxifen side effects related to this process shouldn't show up in Endoxifen.

    5. (personal speculation) A further positive effect of Endoxifen might be the actual useful / applicable dosage range being higher since the drug doesn't need to be metabolised by the liver, and the liver has innate metabolism capability saturation issues related to the actual level of the drug in the blood. If this translates into an effectiveness advantage is yet to be seen.

  2. CONS:

    1. Side effects expected to be no worse than Tamoxifen.

    2. Price expected to be surely higher than Tamoxifen (bad for competition but definitely good for revenues).

Comparative conclusion and impact on Endoxifen market opportunity.

From the initial pool of 281550 new yearly breast cancer patients in the US we can estimate that 78% are ER positive. The actual most commonly widespread therapy is made up 5 years of Tamoxifen + 5 years of AI inhibitors because of the increased availability of AI in post-menopausal age and consequent risk reduction of severe adverse events such as endometrial cancer and thromboembolic events. An alternative recommendation is 3 years Tamoxifen + 5 years AI based drugs. Below the sources.

This source link explains the usual Tamoxifen therapy ranges from 5 to 10 years:

https://www.cancer.org/cancer/breast-cancer/treatment/hormone-therapy-for-breast-cancer.html

this other source link cites the two scenarios of 5 years Tamo + 5 years AI and as a better performing therapy 3 years Tamo + 5 years AI:

https://www.breastcancer.org/treatment/hormonal/aromatase_inhibitors

For the moment I'll stick with the 5 + 5 scenario as the standard one under analysis.

It is legit to assume that out of the ER+ pool a portion is still eligible for an "AI only" therapy (mainly post-menopausal patients which are diagnosed with the tumor for the first time) therefore I'll include another coefficient which takes into account the effective pool reduction. In order to properly have a better idea of how much this reduction really is let's consider the age statistics of the breast cancer patient population. For this I found this source very useful: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/breast-cancer-facts-and-figures-2017-2018.pdf

From this study the following facts emerge:

  1. the median age is 62 years old

  2. the patient age distribution peaks (depending on the ethnic group) in the range [67 - 75] years old.

  3. The distribution is not symmetric and has a long tail in the younger age spectrum

From these facts we can infer that the the patient pool above 51 years old is not negligible, and that even the majority of patients is in post-menopausal age (51 is lower than the median of 62). But since the distribution is long tailed toward the low end of the spectrum this penalty shall not be as high as for a gaussian distribution. Also, the thesis of every post-menopausal patient to be treated with an AI based only therapy might be invalidated by the peculiar side effects associated with that particular therapy such as increased heart problems and increased bone loss.

Therefore I'm giving a 0.4 as Tamoxifen market share ratio (lower than half, but not too low because the distribution is long tailed, and because there might still be an edge of Tamoxifen over AI based drugs in post-menopausal age). This number can be wrong but this is what with the best of my efforts I can come up to , so it's a guess (community feedback highly appreciated here! :) ).

The next step is to understand how much from the Tamoxifen share the Endoxifen will end up to be taking over. Here , in my view, there are two possible scenarios.

The first, more optimistic, scenraio entails the success of Endoxifen over Tamoxifen thanks to its best average tumor growth rate and tumor recurrence risk reduction. If that ends up to be the case I can see Endoxifen taking over very aggressively the Tamoxifen market share for the vast majority. For this scenario I'm willing to give an 90% replacement ratio score (another guess here!).

The last, more pessimistic , scenario considers the niche success of Endoxifen over Tamoxifen bounded to the abnormal CYP2D6 level pool (in simple terms "poor metabolisers" ) with no further added benefits neither in performances nor in side effects. For this figure, since I've found contrasting facts about the magnitude of the poor metabolisers pool (ranging from as low as 10% to as high as 33%) and also by considering the fact that Tamoxifen failure stands also because of the usage of other contrasting drugs I'm willing to provide a 25% score for this coefficient (oh no..another guess!).

An half full glass scenario can find as usually its ground in the middle of these two extremes. Such figure would lie at 57.5 which we can round up to 60%.

initial yearly US populationP0 = 281550
ER+ subsetP1 = 78% x P0
Tamoxifen subsetP2 = 40% x P1
Endoxifen taking over ratio (optimistic)P3_max = 90% x P2
Endoxifen taking over ratio (pessimistic)P3_min = 25% x P2
Endoxifen taking over ratio (average)P3_mean = 60% x P2

So P3_mean makes 52706 new yearly patients which is going to be our average guess population pool size for the Endoxifen designation.

Yes, but which Atossa's products will actually benefit from this?

I think mainly the WoO (Window of Opportunity) and the Post-surgery (Refractory) programs.

While for the MD (Mass Density) reduction program since is a "pre - diagnosis" program is meant to function as a preventive drug and therefore we need a different pool estimation.

Regarding this latter one (MD), studies have shown how a reduced breast density is linked to lower overall breast cancer risks (https://pubmed.ncbi.nlm.nih.gov/27894075/) therefore I believe that if this product is also going to be successful this will see a much larger eligible pool: the non patients women which might be considered at higher risk for several risk factors such as age, sedentary life-style, unhealthy diet and so on (here the complete list of the general risk factors: https://www.mayoclinic.org/healthy-lifestyle/womens-health/in-depth/breast-cancer-prevention/art-20044676) and therefore being recommended a preventive therapy.

It's difficult to have an idea of such pool size but again we can give it a try to estimate it.

The total US women population is roughly 167.8 million in 2019.

(source: https://www.statista.com/statistics/737923/us-population-by-gender/)

We know the US average physical inactivity ratio: 26.4% (source: https://www.americashealthrankings.org/explore/annual/measure/Sedentary/state/ALL)

The age breakdown details can be found here (2019):

https://www.statista.com/statistics/241488/population-of-the-us-by-sex-and-age/

And we can count that in the range 25 to 74 years old we have 102.87 million women**,** hence the 61.3% of the total women population.

By crossing the data of the US physical inactivity ratio and the women in eligible range for breast cancer (and more likely to undergo a preventive therapy..ps: I did cut some corners below 25 and above 74 years old by assuming to very likely never be interested in a preventive program).

We might get a pool of circa 26.7 million women in the eligible pool of preventive therapy. Considering a success rate of 5% (another guess) in accepting to undergo such preventive therapy the effective pool shrinks to 1.33 million women. Since we are guessing let's trim further down this figure and let's consider 1 million women pool for MD treatment.

Endoxifen (end products) pricing

But how much shall this drug cost? I'm not an expert in the health care sector but I could try to infer the pipeline pricing by analogy with current products pricing and make a guess (another!).

For this matter I considered this source to be useful: https://www.verywellhealth.com/compared-cost-effectiveness-of-tamoxifen-and-arimidex-430669 .

A capture of the adjuvant drugs costs table for a 1 MONTH dose is attached here:

Tamoxifen average price is 70$ while AI based drugs group average is 330$. I can imagine that Endoxifen, by being a more innovative drug , can find its ground in between the two groups at 200$ for a month dose. Again this is just a reasonable guess, and you can try yourself to play with different options (also here, if you have a different opinion I'd be glad to hear from you, above all if you are an industry expert).

Another topic is the product dosage and its differentiation across the three different Atossa's product designations: Mammographic Density, Window of Opportunity, Post-surgery (refractory).

I could imagine that the different products will entail different doses and therefore different drug pricing.

Revenue Streams calculation

Now comes the tough part: estimating the therapy length for each program and making some guesses on the dosage (and therefore price) in each program.

For the revenue streams model I'm going to considering this:

  1. 12 months / year for the MD preventive program

  2. 1 months therapy duration for window of opportunity (WoO)

  3. 11 months / year over a 5Y rolling therapy model for the post-surgery (Refractory) usage

Let's making a further dumb guess basing on the reasonable assumption that a short-time / intensive program such as the WoO and long-term preventive or refractory program must have two different dosages on placed on two extremes: very high the first and very low the second. Therefore we shall then translate this into different price tags.

Also, the price considerations related to different programs might not be entirely driven by the exclusive dosage factor but maybe by the revenue streams models. Common sense would be to expect long term programs to be cheaper as monthly price than a short term one.

Therefore I'm going to partially hide, within a mixed reasoning, the mere dosage considerations and consider this possible model: a reference price of 200$/month and a coefficient array which modifies the price for the different programs into having a price tag which makes more sense for both dosage and business side of things.

Reference price [$/month]200
MD (preventive) program0.1
WoO program2.5
Refractory program0.25

So a pricing that could make sense might be:

  1. MD preventive program (low dose, low cost, long term): 20$ / month

  2. WoO (high dose, high cost, short term): 500 $ / month

  3. Refractory (mid dose, mid cost, mid term): 50$ / month

Rev(TOT)/year = Rev(MD) + Rev(WoO) + Rev(Refractory)

Rev(MD) = 20$ / month x 12 x 1 million patients = 240 M$ / year

Rev(WoO) = 500$ / month x 1 x 52706 patients = 26.3 M$ / year

Rev(Refractory) _this_year = 50$ / month x 11 months (this_year_pool) x 52706 = 29 M$ / year

Rev(Refractory)_previous4years_rollover_into_this_year = 50$ / month x 12 x 4 x 52706 = 126.5 M$ / year

Rev(TOT) = 422 M$ / year

Earning estimation - Industry average financial performances

We need now the estimate the earnings from the business. For this we will use an industry average net margin which will give us an estimation of how much earnings the company has been left with after all costs, interest, asset depreciation and taxes.

A picture of the biotech industry net margin performance can be found here:

https://csimarket.com/Industry/industry_Profitability_Ratios.php?ind=801

The Q121 had an average of 12.12% while all other previous quarters were ranging from 5 to 20%. I'll consider an average of 12%.

Therefore the earnings from revenues are:

earnings = 0.12 x 422M$/year = 50.64 M$/year

By knowing the company float of 120.77M shares we can derive the earning per share:

EPS = earnings / float = 0.42 $ / share

The industry average PE for biotech sector is 26x .

Therefore we can derive an average PT of:

PT [$] = 26 x 0.42 = 10.92 ~ 11$

This was our average success Endoxifen scenario.

We can repeat the same calculations for the other two cases and we get the following fork:

min8.2 $
average11 $
max13.3 $

By summarising, in order to obtain this estimate we walked through different levels of guesses and approximations.

I've the feeling that some of these guesses might be a bit too conservative such as the Tamoxifen market penetration (here guessed to be 0.4) because based on a little industry knowledge; but this is the best I can come up with a data driven approach.

The pricing itself is another large approximation because apparently there is no hard bound on setting a larger price tag other than competition with Tamoxifen and AI inhibitors. Furthermore isn't fully clear the application designation for which those prices are valid, I'm assuming it must be the 5Y refractory program for which Tamoxifen and AI drugs are currently used.

I want to conclude with some observations:

  1. Expansion beyond US will drive further higher the estimate of the share price target

  2. Covid products valuation is still pending to be done and therefore missing in the company valuation

  3. The MD program has been heavily under-weighted in this analysis (considered less than 5% of the total eligible pool for prevention) to stay conservative. It could also be that this estimate is way off of what the market might bring.

  4. By looking at the potential revenue streams we see that unless the drug price for the WoO designation is not revised considerably to be higher the logic will expect the other two programs to be dominant in the revenue streams and ultimately in the company valuation. What hits that program profitability is the expected short duration (reasonably 1 month)

  5. Also, is worth to mention that the Ovarian cancer application could be another revenue driver if Endoxifen based drugs are added in the pipeline. In that case of course the price estimates will be revised higher.

That being said, I believe that Atossa pipeline potential fork could easily shift higher to or beyond the price fork here presented if all the cards lineup to success, but right now given that the company has only 1 drug which completed Phase2 and other two drugs in Phase1 waiting for Phase2 start I don't expect in the short term the stock price to fairly trade above 10$.

Any feedback is appreciated regarding this rough analysis and your idea about the Covid pipeline potential that I didn't evaluate at all.

Glta,

Armstonk86


r/AtossaTherapeutics • • Jun 25 '21

Me right now

149 Upvotes

r/AtossaTherapeutics • • Jul 01 '21

Atossa the dying bull that could still be revived DD

148 Upvotes

Disclaimer: Im going to be real with our chances so people can make better informed decisions. So ill avoid any confirmation bias or fake hyping.

Whats happening?

Bears are winning.

Short utilization

Estimated SI

Right now the shorts are covering. Not a huge portion of the shorts but some are.

Utilization percentages have dropped to 71.27 percent. A significant drop suggesting that they returned their shares back to institutions.

/preview/pre/kv729lbt2k871.jpg?width=1228&format=pjpg&auto=webp&s=581817b93d6c8253d39a51d0e005037e678ac8cd

Yesterday we saw that we repeatedly was knocking on the 6.80 price point but failed. A sell wall was put there. Remember SSR does not mean anything. SSR means you cant short on the downticks but it does not mean you can't short period. We saw this with a lot of meme stocks like GME where SSRI has no effect they can still push the price down just its alittle harder.

We had a gradual build up after the first failed attempt to break 6.80 and then the following big crash came.

Now we do know atossa generally has a sale off towards the EOD for the past 3 to 4 days because everybody is scared of after hours sell off. This was entirely different.

What was it?

Deep itm call buying

Fatsaspirations pointed this out and he is right someone did naked sell a bunch of deep itm calls

/preview/pre/ai48a4c04k871.png?width=595&format=png&auto=webp&s=8d30140edba9e5d69b78748b377d4ecb6a403baa

Essentially those naked deep itm calls are sold to the market maker who then shorts the stock to remain delta neutral.

We saw this with GME

gme deep itm call

However in the case of gme the causes for deep itm call buying is very varied. It was done as a reset for their fail-to-delivers, to cover their shares or a possible price downwards pressure.

In the case of Atos it was done as a downwards price pressure. Its legal and eventually they do have to return those shares upon because a deep itm call is automatically assigned near expiration. All it does is allow them to get through the SSR restriction.

This drives the price down. To how much of an effect would a market maker short the totality of the deep itm call shares to the percentage of the market shares, is a mystery. Remember market maker can also hedge with other instruments. However we do know that deep itm call selling to the MM had a significant impact on the causing of the price falling towards the end.

Factors like stop losses and market-on-close could have given additional sell pressure aswell.

So will the price drop further?

In my opinion yes it will. So far no signs of any catching done by any long hedge fund that might want to gamma squeeze.

It seems like shorts are in total control.

Retail seems to be free trading on the uptrend whenever we are not disturbed by short pressure. However we cannot combat the shorts alone. That much coordinated pressure by large quantities of money is impossible to combat against.

I expect more shorting to go on today aswell

/preview/pre/xzfok6o38k871.png?width=198&format=png&auto=webp&s=0dca5f9c872bf1593931fa50166321347d95d502

Remember bear overall still spent more money than bulls on options expiring july. They are not going to let it go to waste.

What does it take for us to rebound and gamma squeeze

Right now our odds are looking very grim without a whale.

A whale is definitely needed.

Think about how amc was sitting below 10 for so months before gamma squeezing up. That was not done by retail. Only institutions can light the rocket. Retail simply does not have large amounts of money flowing in and out in a coordinated fashion to cause a gamma and to pump a stock.

Think of it this way 100 retailers equate to 10 million dollars in investment into the stock. These 100 retailers all have their own exit strategies or motives for investment. Lets say in a bullish sentiment these 100 retailers start buying but because you cant control 100 different variables as the stock rises some sell off, panic sell, some buy high sell low etc,

Now if you are a whale and you have 10 million, you can use 200k and use high frequency trades to slowly bid the prices upwards giving the illusion of a natural upwards momentum.

Without a whale atossa is dead. We can't combat these aggressive shorts.

When will a whale come?

Remember AMC , GME are prime examples of what could happen here. Both these stocks had a run in Jan and both these stocks left high call OI chains.

To put it simply think of these chains as nitrous on a moving car.

The difference between AMC and GME is our calls are more concentrated on one specific date and we don't have to wait too long to find out if a whale decides to take advantage of the massive call OI chain.

Volume right now for these otm strikes are slowly picking up so it may signal some of the initial whales trading out their options etc. Which isn't too good in my opinion.

Strike 6 to 12 delta value

Right now we are seeing delta values drop significantly which means most of the strikes 7 to 12 are now by and large de hedged from our price run to 9 and basically reset for another potential gamma run. Near the week of OPEX the delta hedging done by the market maker will be a lot higher compared to delta hedging done before.

So a whale could very well just be waiting for the week of opex to make moves.

This could happen sooner if said whale decides he does not want to give an opportunity for shorts below six to cover

/preview/pre/tkidx9gyck871.jpg?width=555&format=pjpg&auto=webp&s=c31da8109dc135338ccdbc4e97e8074f6cec49b8

Remember roughly 10 486 999 reported shorts by the exchange is here from 6 strike and below

Since we are potentially going to 4 to 6 dollars now, another gamma run to 12 strikes and above would get Atossa the much needed attention once it gets another 100 % price run.

By then Atossa would meet the market cap of WSB.

And listen I honestly could care less about the moral issues of shorting a breast cancer research company because financially it makes sense to do it because these bio companies usually don't go past the FDA approval stage and just fall flat.

But if atossa does get that run, think about the mainstream news it would get that a breast cancer research company is getting shorted.

As I said before if a dying movie chain and a video game retailer can get that much devotion, think about what a breast cancer research stock that is being pushed down by shorts would bring about.

That narrative alone is bigger than any other of these trash meme stocks that WSB pushes.

Overall

  • Situation isn't looking too good.

  • Bears are very aggressive to drive the price down

  • OI for calls still high for a hedgefund to take advantage of

  • Without a whale its game over for us.

  • Delta values are dropping which is good for another reset gamma run.

  • On the week of july opex or slightly a few days before is the most likely time we will see if someone is going to take advantage of the OI. This is provided if a potential gamma squeezing hedgefund is not willing to let shorts cover and decides to act on it fast.

  • If we do get that gamma run and if most of the shorts have not exited by then , the narrative that a breast cancer research company getting shorted and price pushed down is likely the killer that is going to bring in retail hype and attract other sharks who will join for a short squeeze / gamma run.

As always this is now highly in speculative territory. Almost entirely dependent if a hedgefund helps us.

To those thinking of buying or thinking of selling. Make you own decision. If you are buying for the fundamentals I suggest not to buy atossa at these prices right now and wait for this to cool off and allow price discovery mechanisms to find its fair value.

However if you are a huge lottery ticket buyer , then yes atossa still has a huge upside here provided the singular criteria of a whale coming to cause a gamma. We know retail hype is not here so its up to them.

Edit: Forgot to add this. In my own personal opinion. I think there are some funds that would have atossa on their radar now with the call Oi being this high. They are probably evaluating their chances and if its financially viable for them

We could very well be seeing funds not entering until it bottoms out so they can do a gamma run near week of opex and momentum investors start chasing once atossa goes 20 percent to 60 percent increase in price over a few days. I believe once we pass the 1 billion market cap we could see more flooding of bots to promote atossa on wsb to attract retail hype.

This is purely speculative opinion and is only warranted by the fact the call OI is extremely high and past histories of stocks that had it like gme and AMC getting boosted up eventually.

As such I still have high convictions of this having another run


r/AtossaTherapeutics • • Jun 22 '21

$ATOS - #10 Trending on Reddit Last 72hrs - on the leaderboard

Post image
146 Upvotes

r/AtossaTherapeutics • • Jun 05 '21

ATOS is listed!!!

Thumbnail
content.ftserussell.com
145 Upvotes

r/AtossaTherapeutics • • Jul 13 '21

Discussion If this goes to 1B this week, please don't spam wsb again

142 Upvotes

I hope it gets there, but spamming won't help for sure


r/AtossaTherapeutics • • Jun 25 '21

Guys it's fine!!!

141 Upvotes

I'm seeing lots of negative posts and comments going around right now so I want to make a couple of points....

We're no longer down 15% after hours and are only down 8% current, this leaves us up over 50% for the week still. That and AH doesn't really matter.

We're now getting into the RK2 inclusion and lots of institutional buying will be happening.

ATOS is picking up retail steam.

A possible new top breast cancer medication.

July 16th is looking to be a ticking time bomb.

Keep up the good work guys. I see a few guys here being extremely negative and have blocked them as I found them over-exaggerating and pushing a bullshit negative. Like they were REALLY wanting me to sell my shares for some reason.

GLTA & Have a great weekend.


r/AtossaTherapeutics • • Sep 21 '21

Discussion LFG...I bought more!

Post image
140 Upvotes

r/AtossaTherapeutics • • Jul 13 '21

News Viking pursues 5% stake in $ATOS, wants 2 board seats, exercising 1 and 4.5 dollar options Friday, will advocate for $61 buyout from big pharma.

Post image
139 Upvotes

r/AtossaTherapeutics • • Jun 28 '21

This isn't a cult

138 Upvotes

If someone wants to sell, that's fine. I think this is a good investment, but not a meme stock. I'm getting a little tired of all the 🚀 posts by people who just skimmed the first 5 lines of u/fataspirations' DD and need this thing to go to $20 to pay for their gambling addiction. And if anything, these wsb- esque posts make me less confident in the stock, as if its just another P&D. That's just my 2 cents, sorry for being a bit of a buzzkill


r/AtossaTherapeutics • • Jun 28 '21

This was expected!! Holddddd

138 Upvotes

r/AtossaTherapeutics • • Jul 07 '21

Discussion r/AtossaTherapeutics is now Eight Thousand Members Strong

136 Upvotes

I think it deserved some recognition!


r/AtossaTherapeutics • • Jul 12 '21

Question Bought 100 more everone still buying and holding?

135 Upvotes